Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome.
Cardiac I Kr is a critical repolarizing current in the heart and a target for inherited and acquired long-QT syndrome (LQTS). Biochemical and functional studies have demonstrated that I Kr channels are heteromers composed of both hERG 1a and 1b subunits, yet our current understanding of I Kr functional properties derives primarily from studies of homooligomers of the original hERG 1a isolate. Here, we examine currents produced by hERG 1a and 1a/1b channels expressed in HEK-293 cells at near-physiological temperatures. We find that heteromeric hERG 1a/1b currents are much larger than hERG 1a currents and conduct 80% more charge during an action potential. This surprising difference corresponds to a 2-fold increase in the apparent rates of activation and recovery from inactivation, thus reducing rectification and facilitating current rebound during repolarization. Kinetic modeling shows these gating differences account quantitatively for the differences in current amplitude between the 2 channel types. Drug sensitivity was also different. Compared to homomeric 1a channels, heteromeric 1a/1b channels were inhibited by E-4031 with a slower time course and a corresponding 4-fold shift in the IC50. The importance of hERG 1b in vivo is supported by the identification of a 1b-specific A8V missense mutation in 1/269 unrelated genotype-negative LQTS patients that was absent in 400 control alleles. Mutant 1bA8V expressed alone or with hERG 1a in HEK-293 cells dramatically reduced 1b protein levels. Thus, mutations specifically disrupting hERG 1b function are expected to reduce cardiac I Kr and enhance drug sensitivity, and represent a potential mechanism underlying inherited or acquired LQTS.
Sale
Harinath
H
Department of Physiology, University of Wisconsin, Madison, WI, USA.
Wang
Jinling
J
O'Hara
Thomas J
TJ
Tester
David J
DJ
Phartiyal
Pallavi
P
He
Jia-Qiang
JQ
Rudy
Yoram
Y
Ackerman
Michael J
MJ
Robertson
Gail A
GA
D000200:Action Potentials / Q000187:drug effects / Q000235:genetics; D019943:Amino Acid Substitution; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D002460:Cell Line; D051638:Ether-A-Go-Go Potassium Channels / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000235:genetics; D007700:Kinetics; D008133:Long QT Syndrome / Q000235:genetics* / Q000378:metabolism*; D008954:Models, Biological; D020125:Mutation, Missense; D010880:Piperidines; D021122:Protein Subunits / Q000235:genetics / Q000378:metabolism; D011725:Pyridines
D000889:Anti-Arrhythmia Agents; D051638:Ether-A-Go-Go Potassium Channels; C496884:KCNH1 protein, human; D010880:Piperidines; D021122:Protein Subunits; D011725:Pyridines; C063968:E 4031
Biophys J. 2000 May;78(5):2392-404
10777735
J Intern Med. 2006 Jan;259(1):59-69
16336514
Science. 2005 Aug 5;309(5736):897-903
16002581
Biophys J. 1998 Jan;74(1):230-41
9449325
Prog Biophys Mol Biol. 2008 Jan-Apr;96(1-3):357-76
17919688
Pflugers Arch. 2008 Sep;456(6):1137-48
18504605
Mol Pharmacol. 2006 May;69(5):1709-16
16474003
J Biol Chem. 2008 Feb 15;283(7):3702-7
18048364
Circ Res. 1996 Mar;78(3):499-503
8593709
Circ Res. 1997 Nov;81(5):870-8
9351462
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12329-33
11005845
J Gen Physiol. 1996 May;107(5):611-9
8740374
Mol Cell Biol. 2003 Mar;23(6):1856-62
12612061
J Gen Physiol. 2000 Jun;115(6):749-58
10828248
Circulation. 2005 Sep 6;112(10):1384-91
16129795
J Pharmacol Exp Ther. 1992 Aug;262(2):809-17
1501123
Mol Pharmacol. 2000 Feb;57(2):367-74
10648647
Mol Pharmacol. 1996 Jun;49(6):949-55
8649354
Pflugers Arch. 1999 Nov;438(6):843-50
10591073
J Mol Cell Cardiol. 2008 Mar;44(3):571-81
18222468
Novartis Found Symp. 2005;266:136-50; discussion 150-8
16050266
Genomics. 1998 Jul 1;51(1):86-97
9693036
Clin Cardiol. 1993 Sep;16(9):683-6
7902224
Nature. 1996 Feb 29;379(6568):833-6
8587608
FEBS Lett. 1997 Nov 3;417(1):43-7
9395071
J Physiol. 1997 Jul 1;502 ( Pt 1):45-60
9234196
J Gen Physiol. 2002 Nov;120(5):663-76
12407078
Science. 1995 Jul 7;269(5220):92-5
7604285
Am J Physiol Cell Physiol. 2006 Jul;291(1):C165-75
16452156
Methods Mol Med. 2006;128:181-207
17071997
Biochem Biophys Res Commun. 2005 Aug 26;334(2):441-9
16011830
J Biol Chem. 2004 Oct 22;279(43):44690-4
15304481
J Biol Chem. 2002 Dec 6;277(49):47779-85
12270925
Am J Physiol. 1991 Feb;260(2 Pt 2):H393-9
1899980
Circ Res. 1998 Feb 23;82(3):386-95
9486667
Mol Pharmacol. 2001 Dec;60(6):1343-8
11723241
J Physiol. 2006 Feb 15;571(Pt 1):27-42
16339175
Heart Rhythm. 2005 May;2(5):507-17
15840476
Cardiovasc Res. 2005 Aug 15;67(3):388-96
15913580
Biophys J. 2000 Jul;79(1):231-46
10866950
J Biol Chem. 2002 May 24;277(21):18994-9000
11864984
Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1038-49
16227343
J Gen Physiol. 1998 Nov;112(5):637-47
9806971
J Biol Chem. 2007 Mar 30;282(13):9874-9882
17272276
Neuron. 2001 Nov 20;32(4):649-56
11719205
J Physiol. 2002 Apr 1;540(Pt 1):15-27
11927665
Circ Res. 1996 Jul;79(1):79-85
8925572
J Physiol. 1996 Jun 15;493 ( Pt 3):635-42
8799887
Cardiovasc Res. 2000 Oct;48(1):44-58
11033107
Circ Res. 1997 Nov;81(5):719-26
9351446
Circulation. 2007 Jan 23;115(3):361-7
17210839
J Physiol. 1998 Aug 15;511 ( Pt 1):3-14
9679158
J Physiol. 1987 Jun;387:227-50
2443680
Circ Res. 1998 Jun 15;82(11):1206-23
9633920
J Gen Physiol. 2002 Jun;119(6):521-32
12034760
Cell. 1995 Mar 10;80(5):795-803
7889573
Br J Pharmacol. 2007 Aug;151(8):1368-76
17592502
J Gen Physiol. 2000 Mar;115(3):229-40
10694252
Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1088-100
16565318
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12461-6
12209010
Cell. 1995 Apr 21;81(2):299-307
7736582